Clinical Trial Update: A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor [Phase 2]

View source ↗

Summary

A Phase 2 dose-finding study evaluating darbepoetin alfa (KRN321) for the treatment of anemia in subjects with solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia

Drugs mentioned

• KRN321 (Darbepoetin alfa) (Darbepoetin alfa)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Anemia | Phase 2 | Status: COMPLETED